Sentence examples for initial combination with from inspiring English sources

Initial combination with DPP-4 inhibitors and metformin in drug-naïve patients requiring pharmacological treatment for glycemic control, would be another place of the therapy.

In this study patients were randomized to four remission induction treatment groups: group 1, sequential monotherapy (n = 126); group 2, step up combination therapy (n = 121); group 3, initial combination with prednisone (n = 133); group 4, initial combination with MTX and infliximab (n = 128).

Saxagliptin is approved as an adjunct to diet and exercise, as monotherapy or as an initial combination with metformin, to improve glycemic control in adults with type 2 diabetes (United States) [ 9, 10].

In comparison to other sitagliptin and vildagliptin, saxagliptin shows a similar efficacy and safety profile in monotherapy as well as in the initial combination with metformin or as add-on to metformin or a glitazone.

Patients with T2DM were treated with linagliptin 5 mg once daily or placebo as either monotherapy [ 7, 13], add-on to metformin [ 9], add-on to sulfonylurea [ 14], add-on to metformin and a sulfonylurea [ 8], or as initial combination with pioglitazone [ 15].

45– 48 In the 8 multicenter, randomized, double-blind, 24-week, phase 3 trials in which saxagliptin was administered as monotherapy; as initial combination with metformin; or as add-on treatment in patients receiving metformin, glyburide, or TZD, the frequency of hypoglycemia was generally similar to that for placebo or to treatment arms not containing saxagliptin for up to 76 weeks (Table 3).

3– 7 When given as monotherapy, in initial combination with metformin, or in combination as add-on therapy for patients inadequately controlled with an SU or TZD in studies up to 24 weeks, and metformin up to 102 weeks, saxagliptin has documented efficacy in improving glycemic control (measured by HbA1c, FPG, PPG, and proportions of patients achieving HbA1c < 7%) compared with placebo.

Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD).